%0 Generic
%T Commentary on A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines
%A Hausauer, Amelia K.
%I Ovid Technologies (Wolters Kluwer Health)
%@ 1076-0512
%@ 1524-4725
%K Dermatology
%K General Medicine
%K Surgery
%D 2021
%C Ovid Technologies (Wolters Kluwer Health)
%U http://slubdd.de/katalog?TN_libero_mab2
Download citation